Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Galectin Therapeutic (GALT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 75,581
  • Shares Outstanding, K 34,670
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,440 K
  • 36-Month Beta 2.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 113.33

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.05 +7.80%
on 07/24/17
2.56 -13.67%
on 06/27/17
-0.25 (-10.16%)
since 06/23/17
3-Month
2.04 +8.33%
on 05/17/17
3.27 -32.42%
on 04/26/17
-1.06 (-32.42%)
since 04/25/17
52-Week
0.49 +351.02%
on 11/03/16
3.68 -39.95%
on 04/10/17
+0.66 (+42.58%)
since 07/25/16

Most Recent Stories

More News
Patent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has received notice of allowance for a U.S. Patent for "Method...

GALT : 2.21 (+6.76%)
Technical Reports on Generic Drugs Equities -- pSivida, Tetraphase Pharma, Catalyst Pharma, and Galectin Therapeutics

If you want a Stock Review on PSDV, TTPH, CPRX, or GALT then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. A look at consensus earnings expectations...

PSDV : 1.32 (-2.22%)
GALT : 2.21 (+6.76%)
CPRX : 3.04 (-1.30%)
TTPH : 6.90 (-5.48%)
Galectin Therapeutics to Present at the Singular Research Summer Conference

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin, Ph.D., the Company's chief operating officer, will be...

GALT : 2.21 (+6.76%)
Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has received notice of allowance for a U.S. Patent for "Galacto-Rhamnogalacturonate...

GALT : 2.21 (+6.76%)
Autoimmune Disease Patent Granted to Galectin Therapeutics

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has been issued U.S. Patent 9,649,327 for "Composition of...

GALT : 2.21 (+6.76%)
Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of the Liver Line, an online community and publication on liver...

GALT : 2.21 (+6.76%)
Can The Uptrend Continue for Galectin Therapeutics (GALT)?

Investors certainly have to be happy with Galectin Therapeutics Inc (GALT) and its short term performance

GALT : 2.21 (+6.76%)
Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin diseases, and cancer, today announced that the Company has received...

GALT : 2.21 (+6.76%)
Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings?

Henry Schein, Inc. (HSIC) is expected to report first-quarter 2017 results on May 2, before the opening bell.

SYRS : 22.14 (+7.68%)
GALT : 2.21 (+6.76%)
HSIC : 184.74 (-0.51%)
HRC : 84.01 (-0.11%)
Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings?

Myriad Genetics, Inc. (MYGN) is scheduled to report third-quarter fiscal 2017 results on May 2, after the closing bell.

SYRS : 22.14 (+7.68%)
GALT : 2.21 (+6.76%)
MYGN : 23.86 (-1.24%)
HRC : 84.01 (-0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring...

See More

Support & Resistance

2nd Resistance Point 2.50
1st Resistance Point 2.35
Last Price 2.21
1st Support Level 2.07
2nd Support Level 1.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.